Filing Details

Accession Number:
0001140361-15-028590
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-07-24 16:36:50
Reporting Period:
2015-07-22
Filing Date:
2015-07-24
Accepted Time:
2015-07-24 16:36:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
946486 Discovery Laboratories Inc DSCO Biological Products, (No Disgnostic Substances) (2836) 943171943
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1164287 G John Cooper 2600 Kelly Rd
Suite 100
Warrington PA 18976
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-07-22 41,667 $0.00 64,313 No 4 P Direct
Common Stock Acquisiton 2015-03-31 2,836 $1.19 42,547 No 5 A Indirect By Trust
Common Stock Acquisiton 2015-06-30 4,964 $0.68 47,511 No 5 A Indirect By Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 5 A Indirect By Trust
No 5 A Indirect By Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Warrants (Right to Buy) Acquisiton 2015-07-22 41,667 $0.00 41,667 $0.70
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
41,667 2015-07-22 2022-07-22 No 4 P Direct
Footnotes
  1. Common Stock in connection with the purchase of Series A units acquired in an underwritten public offering of Series A units and Series B units with a unit purchase price of $0.60. Each Series A unit consists of one share of common stock and one Series A warrant to purchase one share of common stock at an initial exercise price of $0.70 per share. Refer to Table II for related Series A warrant information.
  2. Transaction reported on Table I represents Issuer's matching stock contribution pursuant to 401(k) plan.
  3. Series A Warrants in connection with the purchase of Series A units acquired in an underwritten public offering of Series A units and Series B units with a unit purchase price of $0.60. Each Series A unit consists of one share of common stock and one Series A warrant to purchase one share of common stock at an initial exercise price of $0.70 per share. Refer to Table I for related common stock information.